Cell line/type | PBMC (peripheral blood mononuclear cells) |
---|---|
Species | Human |
Animal free | Unspecified |
Product | CryoMaxx II/RPMI-DMSO-HSA (cryopreservation) |
Filbert, H., Attig, S., Bidmon, N., Renard, B. Y., Janetzki, S., Sahin, U., ... & Britten, C. M. (2013). Serum-free freezing media support high cell quality and excellent ELISPOT assay performance across a wide variety of different assay protocols. Cancer Immunology, Immunotherapy, 62(4), 615-627. doi: 10.1007/s00262-012-1359-5. The aim of this study was to test whether serum-free freezing media can lead to high cell viability and favorable performance across multiple ELISPOT assay protocols. Self-made and commercially available serum-free freezing media led to higher cell viability and similar cell recovery after thawing and resting compared to freezing media supplemented with human serum. (A) 90% human AB serum + 10% DMSO (B) CryoMaxx II (PAA) (C) 10% human serum albumin + 10% DMSO + 80% RPMI were tested. The results generated both in the proficiency panel and in the single-center study provide a firm basis for the recommendation to use serum-free media for freezing of PBMCs collected throughout clinical testing. The use of defined media for freezing and testing of PBMCs may lead to a higher reproducibility of results generated over time and across institutions and less delays when importing cell material in multinational trials. The authors concluded that defined and accessible serum-free freezing media should be recommended for freezing cells stored for subsequent ELISPOT analysis. CryoMaxx II (group B) is a commercially available medium. The precise formulation is proprietary. The formulation of the RPMI-DMSO-HSA based medium (group c) is listed in the Materials and Methods. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3624011/pdf/262_2012_Article_1359.pdf |
|
Source | Literature - own formulation |
Chemically defined > Unspecified | Unspecified |